Apyx Medical Corporation Reports Third Quarter 2025 Financial Results CLEARWATER, FL — November 6, 2025 - Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its quarter ended September 30, 2025. Recent Financial and Operating Highlights: "In September, we successfully transitioned the commercialization program for AYON from an effective soft ...

Clinical Trials - Completed enrollment in the Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa, with topline data expected in mid-2026[5] - The LOTUS trial includes approximately 250 adults to evaluate the efficacy and safety of AVTX-009 with two dosing regimens compared to placebo[6] Financial Performance - Net loss for Q3 2025 was $30.6 million, compared to net income of $23.0 million for Q3 2024, with a significant change in other expenses[7] - Basic and diluted net loss per share for Q3 2025 was $2.19, compared to basic net income per share of $0.98 for Q3 2024[7] - Research and development expenses for Q3 2025 were $13.6 million, an increase of $4.1 million from Q3 2024, driven by costs related to the LOTUS trial[6] - General and administrative expenses for Q3 2025 were $5.6 million, an increase of $1.3 million from Q3 2024, primarily due to stock-based compensation[6] Assets and Liabilities - Cash and short-term investments totaled approximately $112 million as of September 30, 2025, expected to fund operations into 2028[5] - Total current assets as of September 30, 2025, were $113.8 million, down from $138.9 million as of December 31, 2024[8] - Total liabilities increased to $33.6 million as of September 30, 2025, compared to $17.7 million as of December 31, 2024[8] Leadership and Personnel - The leadership team was expanded with key appointments, including Taylor Boyd as Chief Business Officer and Ashley Ivanowicz as Senior Vice President of Human Resources[5] Risks and Uncertainties - Avalo Therapeutics may face significant risks and uncertainties that could cause actual results to differ from forward-looking statements[15] - The company relies on key personnel and is subject to regulatory risks that may impact its operations[16] - Economic and market risks, including geopolitical tensions such as the war in Ukraine and the Middle East, could affect Avalo's performance[16]

Exhibit 99.1 D-Wave Reports Third Quarter 2025 Results Q3 and YTD Revenue up 100% and 235% Year over Year Respectively Q3 and YTD GAAP Gross Profit up 156% and 353% Year over Year Respectively Highest Cash Balance in Company's History at over $836 Million PALO ALTO, Calif. – November 6, 2025 – D-Wave Quantum Inc. (NYSE: QBTS) ("D-Wave" or the "Company"), a leader in commercial quantum computing systems, software, and services, today announced financial results for its third fiscal quarter ended September 30 ...

Exhibit 99 1201 S. Second Street Milwaukee, WI 53204 USA News Release Contact Ed Moreland Media Relations Rockwell Automation 571.296.0391 Aijana Zellner Investor Relations Rockwell Automation 440.289.8439 Rockwell Automation Reports Fourth Quarter and Full Year 2025 Results; Introduces Fiscal 2026 Guidance MILWAUKEE (November 6, 2025) – Rockwell Automation, Inc. (NYSE: ROK) today reported fiscal 2025 fourth quarter and full year results and introduced fiscal 2026 guidance. "We entered fiscal 2025 with a cl ...

Financial Performance - Third quarter net revenue was $1.20 billion, a decrease of $168 million or 12.3% year-over-year, primarily due to lower political advertising revenue [2]. - Distribution revenue for Q3 was $709 million, down $10 million or 1.4% compared to the prior year, reflecting subscriber attrition and non-recurring customer claims [2]. - Advertising revenue decreased to $476 million, down $146 million or 23.5% year-over-year, mainly due to a $145 million drop in political advertising [2]. - Net income for the third quarter was $65 million, a decline of $115 million or 63.9% compared to the previous year, with a net income margin of 5.4% [2]. - Adjusted EBITDA was $358 million, down $152 million or 29.8% year-over-year, with an adjusted EBITDA margin of 29.9% [12]. - Net revenue for Q3 2025 was $1,198 million, a decrease of 12.3% compared to $1,366 million in Q3 2024 [27]. - Operating income for the nine months ended September 30, 2025, was $607 million, down 28.6% from $851 million in the same period of 2024 [27]. - Net income attributable to Nexstar Media Group, Inc. for Q3 2025 was $70 million, a decline of 62.7% from $187 million in Q3 2024 [27]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $1,128 million, a decrease of 18.1% compared to $1,376 million in the same period of 2024 [31]. - Free Cash Flow for Q3 2025 was $87 million, down 75.7% from $358 million in Q3 2024 [35]. - Total operating expenses for the nine months ended September 30, 2025, were $3,053 million, a slight decrease from $3,069 million in the same period of 2024 [27]. - Interest expense, net for the nine months ended September 30, 2025, was $288 million, down 15.3% from $340 million in the same period of 2024 [27]. - Corporate operating expenses increased to $68 million in Q3 2025 from $53 million in Q3 2024, reflecting a 28.3% rise [27]. Cash Flow and Debt - Net cash provided by operating activities was $117 million, a decrease of $270 million or 69.8% year-over-year [12]. - Adjusted free cash flow for Q3 was $166 million, down $161 million or 49.2% compared to the prior year [12]. - As of September 30, 2025, total debt was $6.36 billion, with a first lien net leverage ratio of 1.73x [16]. - Cash and cash equivalents at the end of Q3 2025 were $236 million, an increase from $181 million at the end of Q3 2024 [29]. Strategic Developments - The company entered into a definitive agreement to acquire TEGNA Inc. for $6.2 billion, expected to be accretive to standalone adjusted free cash flow [8]. - NewsNation was the fastest growing cable network year-over-year through September 2025, while The CW achieved its sixth consecutive quarter of audience growth [8]. Shareholder Information - The weighted average number of common shares outstanding for Q3 2025 was 30,319 thousand, compared to 32,020 thousand in Q3 2024 [27].

FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 28, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of Registrant as specified in its charter) Delaware 61-1203323 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification number) 2002 Papa John's Boulevard Louisville, KY 40299-2367 (Address of principal executive offices) (Zip Co ...

Financial Performance - Black Diamond Therapeutics reported a net loss of $8.5 million for Q3 2025, an improvement from a net loss of $15.6 million in Q3 2024[5]. - Total operating expenses for Q3 2025 were $10.98 million, compared to $18.13 million in Q3 2024[13]. - The accumulated deficit as of September 30, 2025, was $449.6 million, reduced from $487.1 million at the end of 2024[11]. - License revenue for the nine months ended September 30, 2025, was $70 million, with no license revenue reported for the same period in 2024[13]. Research and Development - Research and development expenses decreased to $7.4 million in Q3 2025 from $12.9 million in Q3 2024, primarily due to workforce efficiencies and outlicensing of BDTX-4933[5]. - Black Diamond plans to disclose objective response rate (ORR) and preliminary duration of treatment data from the Phase 2 trial of silevertinib later this quarter[4]. - Black Diamond is exploring partnership opportunities in NSCLC and glioblastoma to advance silevertinib into pivotal development[5]. - The company intends to seek FDA feedback on a potential registrational path for silevertinib in the first half of 2026[5]. Cash and Funding - The company ended Q3 2025 with approximately $135.5 million in cash, cash equivalents, and investments, up from $98.6 million as of December 31, 2024[5]. - The company expects to have sufficient funds to support operations into Q4 2027[6].

Financial Performance - Net sales for Q3 2025 were $982 million, a 4% increase year-over-year, but flat on an organic basis[5] - Adjusted EBITDA for Q3 2025 was $196 million, down from $213 million in the prior year, reflecting a $12 million adverse impact from tariffs[7] - The diluted EPS for Q3 2025 was $(10.15), while adjusted EPS was $2.37, compared to $2.33 in the prior year[5] - Total net sales for the three months ended September 27, 2025, were $982.131 million, an increase from $942.809 million in the same period of 2024, representing a growth of 4.2%[19] - Segment adjusted EBITDA for the three months ended September 27, 2025, was $196.404 million, with an adjusted EBITDA margin of 20.0%, compared to $212.972 million and 22.6% in the prior year[19] - The company reported a net loss of $512.978 million for the third quarter of 2025, compared to a net income of $114.166 million in the third quarter of 2024[24] - For the nine months ended September 27, 2025, total net sales were $2.866617 billion, slightly down from $2.861281 billion in the same period of 2024[21] Segment Performance - Organic net sales growth by segment: Commercial Foodservice at 1.6%, Residential Kitchen at (0.6)%, and Food Processing at (5.6)%[4] - The Food Processing segment saw a 13.2% increase in net sales, driven by improved market dynamics in Q3[4] - Segment operating income for the Commercial segment was $143.350 million, with an operating income margin of 23.7%, while the Residential segment reported an operating loss of $701.546 million[19] Strategic Initiatives - The company reported a non-cash impairment charge of $709 million due to a strategic review of the Residential Kitchen business[5] - The strategic review of the Residential Kitchen business aims to unlock shareholder value and improve long-term growth prospects[3] - The company incurred impairments of $709.116 million in the third quarter of 2025, significantly impacting overall financial performance[24] Cash Flow and Capital Expenditures - Operating cash flows for Q3 2025 were $176.3 million, an increase from $156.7 million in Q3 2024, while for the nine months ended, it decreased slightly to $439.5 million from $447.1 million[25] - Free cash flow for Q3 2025 was $156.1 million, up from $145.2 million in Q3 2024, and for the nine months ended, it decreased to $364.6 million from $410.9 million[25] - Capital expenditures for Q3 2025 were $20.3 million, compared to $11.5 million in Q3 2024, and for the nine months ended, it increased to $74.9 million from $36.2 million[25] Future Projections - For Q4 2025, total revenue is expected to be between $990 million and $1.02 billion, with adjusted EBITDA projected at $200-210 million[10] - The company’s net leverage ratio stands at 2.3x, with net debt at $1.9 billion[10] Non-GAAP Financial Measures - Non-GAAP financial measures are used by the company to provide greater insight into its financial performance, focusing on organic net sales growth and adjusted EBITDA[27] - The company believes that adjusted net earnings and adjusted diluted per share measures are useful for evaluating its operations and financial performance[27] - The company aims to provide investors with the same information it uses internally for assessing core operating performance through its non-GAAP financial measures[29] - The company’s net debt and net leverage are key metrics for evaluating its financial health and operational performance[27] - The company’s management primarily focuses on non-GAAP items for business planning purposes, as they believe these measures reflect core operating performance more accurately[27] Shareholder Actions - The company repurchased 3.5 million shares year-to-date for approximately $500 million, representing 6.4% of equity[5] - The company incurred strategic transaction costs of $6.1 million for Q3 2025 and $16.4 million for the nine months ended September 27, 2025[25] - Corporate and other general company expenses impacted segment adjusted EBITDA, amounting to $20.0 million for the three months ended September 27, 2025[22] - Restructuring expenses for the three months ended September 27, 2025, totaled $2.822 million, compared to $2.519 million in the same period of 2024[24] - Foreign exchange rates positively impacted segment adjusted EBITDA by approximately $1.8 million for the three months ended September 27, 2025[22]

COLUMBIA, SC., November 6, 2025 / United Homes Group, Inc. (the "Company") (NASDAQ: UHG) today announced results for the three and nine months ended September 30, 2025. Third Quarter 2025 Operating Results For the third quarter 2025, net loss was $31.3 million, or $0.53 per diluted share, which included a loss from the change in fair value of derivative liabilities of $27.2 million, with that change predominantly due to changes in fair value on potential earn-out consideration and warrants due to fluctuatio ...

Third Quarter 2025 Highlights COLUMBIA, SC., November 6, 2025 / United Homes Group, Inc. (the "Company") (NASDAQ: UHG) today announced results for the three and nine months ended September 30, 2025. Exhibit 99.1 UNITED HOMES GROUP, INC. REPORTS 2025 THIRD QUARTER RESULTS Third Quarter 2025 Operating Results For the third quarter 2025, net loss was $31.3 million, or $0.53 per diluted share, which included a loss from the change in fair value of derivative liabilities of $27.2 million, with that change predom ...